Intravitreal injection is a drug that is injected directly into the vitreous cavity of the eye and is mainly used to treat various fundus diseases.
The global Intravitreal Injection market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The “Intravitreal Injection Industry Forecast” looks at past sales and reviews total world Intravitreal Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Intravitreal Injection sales for 2024 through 2030. With Intravitreal Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intravitreal Injection industry.
This Insight Report provides a comprehensive analysis of the global Intravitreal Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Intravitreal Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Intravitreal Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intravitreal Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intravitreal Injection.
United States market for Intravitreal Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Intravitreal Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Intravitreal Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Intravitreal Injection players cover Sanofi, Novartis, Bayer, Genentech and Apellis Pharmaceuticals, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Intravitreal Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Ranibizumab
Bevacizumab
Aflibercept
Brolucizumab
Faricimab
Others
Segmentation by application
Diabetic Eye Disease
AMD
Retinal Vein Occlusion
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Novartis
Bayer
Genentech
Apellis Pharmaceuticals, Inc.
Coherus BioSciences Inc.
Iveric Bio
Regeneron
Roche
Qilu Pharmaceutical Co.,Ltd.
Chengdu Kanghong Pharmaceutical Group
Key Questions Addressed in this Report
What is the 10-year outlook for the global Intravitreal Injection market?
What factors are driving Intravitreal Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Intravitreal Injection market opportunities vary by end market size?
How does Intravitreal Injection break out type, application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Intravitreal Injection Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Intravitreal Injection by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Intravitreal Injection by Country/Region, 2019, 2023 & 2030
2.2 Intravitreal Injection Segment by Type
2.2.1 Ranibizumab
2.2.2 Bevacizumab
2.2.3 Aflibercept
2.2.4 Brolucizumab
2.2.5 Faricimab
2.2.6 Others
2.3 Intravitreal Injection Sales by Type
2.3.1 Global Intravitreal Injection Sales Market Share by Type (2019-2024)
2.3.2 Global Intravitreal Injection Revenue and Market Share by Type (2019-2024)
2.3.3 Global Intravitreal Injection Sale Price by Type (2019-2024)
2.4 Intravitreal Injection Segment by Application
2.4.1 Diabetic Eye Disease
2.4.2 AMD
2.4.3 Retinal Vein Occlusion
2.4.4 Others
2.5 Intravitreal Injection Sales by Application
2.5.1 Global Intravitreal Injection Sale Market Share by Application (2019-2024)
2.5.2 Global Intravitreal Injection Revenue and Market Share by Application (2019-2024)
2.5.3 Global Intravitreal Injection Sale Price by Application (2019-2024)
3 Global Intravitreal Injection by Company
3.1 Global Intravitreal Injection Breakdown Data by Company
3.1.1 Global Intravitreal Injection Annual Sales by Company (2019-2024)
3.1.2 Global Intravitreal Injection Sales Market Share by Company (2019-2024)
3.2 Global Intravitreal Injection Annual Revenue by Company (2019-2024)
3.2.1 Global Intravitreal Injection Revenue by Company (2019-2024)
3.2.2 Global Intravitreal Injection Revenue Market Share by Company (2019-2024)
3.3 Global Intravitreal Injection Sale Price by Company
3.4 Key Manufacturers Intravitreal Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Intravitreal Injection Product Location Distribution
3.4.2 Players Intravitreal Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Intravitreal Injection by Geographic Region
4.1 World Historic Intravitreal Injection Market Size by Geographic Region (2019-2024)
4.1.1 Global Intravitreal Injection Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Intravitreal Injection Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Intravitreal Injection Market Size by Country/Region (2019-2024)
4.2.1 Global Intravitreal Injection Annual Sales by Country/Region (2019-2024)
4.2.2 Global Intravitreal Injection Annual Revenue by Country/Region (2019-2024)
4.3 Americas Intravitreal Injection Sales Growth
4.4 APAC Intravitreal Injection Sales Growth
4.5 Europe Intravitreal Injection Sales Growth
4.6 Middle East & Africa Intravitreal Injection Sales Growth
5 Americas
5.1 Americas Intravitreal Injection Sales by Country
5.1.1 Americas Intravitreal Injection Sales by Country (2019-2024)
5.1.2 Americas Intravitreal Injection Revenue by Country (2019-2024)
5.2 Americas Intravitreal Injection Sales by Type
5.3 Americas Intravitreal Injection Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Intravitreal Injection Sales by Region
6.1.1 APAC Intravitreal Injection Sales by Region (2019-2024)
6.1.2 APAC Intravitreal Injection Revenue by Region (2019-2024)
6.2 APAC Intravitreal Injection Sales by Type
6.3 APAC Intravitreal Injection Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Intravitreal Injection by Country
7.1.1 Europe Intravitreal Injection Sales by Country (2019-2024)
7.1.2 Europe Intravitreal Injection Revenue by Country (2019-2024)
7.2 Europe Intravitreal Injection Sales by Type
7.3 Europe Intravitreal Injection Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Intravitreal Injection by Country
8.1.1 Middle East & Africa Intravitreal Injection Sales by Country (2019-2024)
8.1.2 Middle East & Africa Intravitreal Injection Revenue by Country (2019-2024)
8.2 Middle East & Africa Intravitreal Injection Sales by Type
8.3 Middle East & Africa Intravitreal Injection Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Intravitreal Injection
10.3 Manufacturing Process Analysis of Intravitreal Injection
10.4 Industry Chain Structure of Intravitreal Injection
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Intravitreal Injection Distributors
11.3 Intravitreal Injection Customer
12 World Forecast Review for Intravitreal Injection by Geographic Region
12.1 Global Intravitreal Injection Market Size Forecast by Region
12.1.1 Global Intravitreal Injection Forecast by Region (2025-2030)
12.1.2 Global Intravitreal Injection Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Intravitreal Injection Forecast by Type
12.7 Global Intravitreal Injection Forecast by Application
13 Key Players Analysis
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Intravitreal Injection Product Portfolios and Specifications
13.1.3 Sanofi Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Intravitreal Injection Product Portfolios and Specifications
13.2.3 Novartis Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Bayer
13.3.1 Bayer Company Information
13.3.2 Bayer Intravitreal Injection Product Portfolios and Specifications
13.3.3 Bayer Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Bayer Main Business Overview
13.3.5 Bayer Latest Developments
13.4 Genentech
13.4.1 Genentech Company Information
13.4.2 Genentech Intravitreal Injection Product Portfolios and Specifications
13.4.3 Genentech Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Genentech Main Business Overview
13.4.5 Genentech Latest Developments
13.5 Apellis Pharmaceuticals, Inc.
13.5.1 Apellis Pharmaceuticals, Inc. Company Information
13.5.2 Apellis Pharmaceuticals, Inc. Intravitreal Injection Product Portfolios and Specifications
13.5.3 Apellis Pharmaceuticals, Inc. Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Apellis Pharmaceuticals, Inc. Main Business Overview
13.5.5 Apellis Pharmaceuticals, Inc. Latest Developments
13.6 Coherus BioSciences Inc.
13.6.1 Coherus BioSciences Inc. Company Information
13.6.2 Coherus BioSciences Inc. Intravitreal Injection Product Portfolios and Specifications
13.6.3 Coherus BioSciences Inc. Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Coherus BioSciences Inc. Main Business Overview
13.6.5 Coherus BioSciences Inc. Latest Developments
13.7 Iveric Bio
13.7.1 Iveric Bio
Company Information
13.7.2 Iveric Bio
Intravitreal Injection Product Portfolios and Specifications
13.7.3 Iveric Bio
Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Iveric Bio
Main Business Overview
13.7.5 Iveric Bio
Latest Developments
13.8 Regeneron
13.8.1 Regeneron Company Information
13.8.2 Regeneron Intravitreal Injection Product Portfolios and Specifications
13.8.3 Regeneron Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Regeneron Main Business Overview
13.8.5 Regeneron Latest Developments
13.9 Roche
13.9.1 Roche Company Information
13.9.2 Roche Intravitreal Injection Product Portfolios and Specifications
13.9.3 Roche Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Roche Main Business Overview
13.9.5 Roche Latest Developments
13.10 Qilu Pharmaceutical Co.,Ltd.
13.10.1 Qilu Pharmaceutical Co.,Ltd. Company Information
13.10.2 Qilu Pharmaceutical Co.,Ltd. Intravitreal Injection Product Portfolios and Specifications
13.10.3 Qilu Pharmaceutical Co.,Ltd. Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Qilu Pharmaceutical Co.,Ltd. Main Business Overview
13.10.5 Qilu Pharmaceutical Co.,Ltd. Latest Developments
13.11 Chengdu Kanghong Pharmaceutical Group
13.11.1 Chengdu Kanghong Pharmaceutical Group Company Information
13.11.2 Chengdu Kanghong Pharmaceutical Group Intravitreal Injection Product Portfolios and Specifications
13.11.3 Chengdu Kanghong Pharmaceutical Group Intravitreal Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Chengdu Kanghong Pharmaceutical Group Main Business Overview
13.11.5 Chengdu Kanghong Pharmaceutical Group Latest Developments
14 Research Findings and Conclusion
*If Applicable.